Abstract
Aim: The purpose of this study is to design and synthesize a new series of sulfamethazine derivatives as potent neuraminidase inhibitors. Materials & methods: A sulfamethazine lead compound, ZINC670537, was first identified by structure-based virtual screening technique, then some novel inhibitors X1–X10 based on ZINC670537 were designed and synthesized. Results: Compound X3 exerts the most good potency in inhibiting the wild-type H5N1 NA (IC50 = 6.74 μM) and the H274Y mutant NA (IC50 = 21.09 μM). 150-cavity occupation is very important in determining activities of these inhibitors. The sulfamethazine moiety also plays an important role. Conclusion: Compound X3 maybe regard as a good anti-influenza candidate to preform further study.
GRAPHICAL ABSTRACT
A series of novel sulfamethazine neuraminidase inhibitors were designed and synthesized.
A novel lead compound ZINC670537 was screened out by means of structure-based virtual screening, molecular dynamic simulation and bioactivity test.
A series of novel sulfamethazine neuraminidase inhibitors were designed and synthesized.
compound X3 has the best inhibitory activity, and its activity inhibiting the H274Y mutant NA is comparable to that of OSC.
Molecular docking studies have shown that the 150-cavity plays an important role in discovery of novel sulfamethazine NA inhibitors.
The sulfamethazine moiety interacts tightly with three key residues (Arg118, Arg292, Arg371) by forming hydrogen bondings, which is beneficial to improve activity of compound.
The results of this work provide new insights into the design of more potent NA inhibitors.
Supplemental material
Supplemental data for this article can be accessed at https://doi.org/10.1080/17568919.2024.2342688
Financial disclosure
This work was supported by the Collaborative Innovation Fund (XTCX2023) and the Shanghai Municipal Education Commission. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Competing interests disclosure
The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Writing disclosure
No writing assistance was utilized in the production of this manuscript.